Gilead and Galapagos NV Reports Filgotinib (JAK1i) achieve 1EP and 2EP in FINCH-2 P-III study for the Treatment of RA

Gilead and Galapagos NV Reports Filgotinib (JAK1i) achieve 1EP and 2EP in FINCH-2 P-III study for the Treatment of RA

Shots:

  • FINCH-2 trial assessing filgotinib administering qd (200/100mg) vs PBO in ratio (1:1:1) for 24 wks. in moderate-to-severe active RA patients, intolerant to bDMARDs
  • FINCH-2 results (N= ≥153): ACR20@12wk (66 vs 57.5 vs 31.1) & ACR20@24wk (69.4 vs 54.9 vs 34.5) whereas, ACR70@12wk (21.8 vs 14.4 vs 6.8), ACR70@24wk (32.0 vs 20.3 vs 8.1) & DAS28LDA@12 (40.8 vs 37.3 vs 15.5)
  • Filgotinib was well tolerated in FINCH-2 trial with no new safety issues and occurrence of serious adverse events (4.1 %, 5.2 % 3.4 %) in patients
  • Gilead and Galapagos globally collaborated for filgotinib’s development and commercialization. Several trials are assessing filgotinib, including P-III FINCH 2 trial for RA/other inflammatory diseases, the EQUATOR P-II for PA, the TORTUGA study for AS, the DIVERSITY P-III trial for Crohn’s disease and the P-III SELECTION trial for ulcerative colitis

Click here to read full press release/ article | Ref: Gilead | Image: Nikkei Asian